Immunephenotype Predicts Response to Vedolizumab: Integrating Clinical and Biochemical Biomarkers in the Treatment of Inflammatory Bowel Diseases
Sign Up to like & getrecommendations! Published in 2018 at "Digestive Diseases and Sciences"
DOI: 10.1007/s10620-018-5039-y
Abstract: In the past decades, biological agents (engineered monoclonal antibodies [mAbs]) have emerged as essential therapy for moderate-to-severe inflammatory bowel disease (IBD). More recently, the mAb tumor necrosis factor-α antagonists (anti-TNFα), infliximab, adalimumab, golimumab, and certolizumab… read more here.
Keywords: bowel; vedolizumab; response; treatment ... See more keywords